Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Bieche

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Gut|September 27, 2007
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CT Asselah, I Bieche, S Narguet, et al.
British Journal of Cancer|April 25, 2013
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumabM Cizkova, M-E Dujaric, J Lehmann-Che, et al.
Endocrine-Related Cancer|September 17, 2004
Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reactionP de Cremoux, I Bieche, C Tran-Perennou, et al.
Journal of Thrombosis and Haemostasis : JTH|January 31, 2012
The profibrotic cytokine transforming growth factor-β1 increases endothelial progenitor cell angiogenic propertiesS M Evrard, C d'Audigier, L Mauge, et al.
Analytical and Quantitative Cytology and Histology|November 24, 1999
Alteration of Met protooncogene product expression and prognosis in breast carcinomasI Tsarfaty, W G Alvord, J H Resau, et al.
Journal of Viral Hepatitis|October 15, 2013
IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patientsQ Zhang, M Lapalus, T Asselah, et al.
Gynecologic Oncology Reports|September 20, 2021
Tumor <i>BRCA</i> testing can reveal a high tumor mutational burden related to <i>POLE</i> pathogenic variantsM-C Villy, J Masliah-Planchon, S Melaabi, et al.
Oncogene|September 25, 2007
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancerW N Cooper, R E Dickinson, A Dallol, et al.
Breast Cancer Research and Treatment|September 5, 2016
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapyA S Hamy, I Bieche, J Lehmann-Che, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)R Condorelli, F Mosele, B Verret, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Gut|September 27, 2007
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CT Asselah, I Bieche, S Narguet, et al.
British Journal of Cancer|April 25, 2013
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumabM Cizkova, M-E Dujaric, J Lehmann-Che, et al.
Endocrine-Related Cancer|September 17, 2004
Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reactionP de Cremoux, I Bieche, C Tran-Perennou, et al.
Journal of Thrombosis and Haemostasis : JTH|January 31, 2012
The profibrotic cytokine transforming growth factor-β1 increases endothelial progenitor cell angiogenic propertiesS M Evrard, C d'Audigier, L Mauge, et al.
Analytical and Quantitative Cytology and Histology|November 24, 1999
Alteration of Met protooncogene product expression and prognosis in breast carcinomasI Tsarfaty, W G Alvord, J H Resau, et al.
Journal of Viral Hepatitis|October 15, 2013
IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patientsQ Zhang, M Lapalus, T Asselah, et al.
Gynecologic Oncology Reports|September 20, 2021
Tumor <i>BRCA</i> testing can reveal a high tumor mutational burden related to <i>POLE</i> pathogenic variantsM-C Villy, J Masliah-Planchon, S Melaabi, et al.
Oncogene|September 25, 2007
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancerW N Cooper, R E Dickinson, A Dallol, et al.
Breast Cancer Research and Treatment|September 5, 2016
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapyA S Hamy, I Bieche, J Lehmann-Che, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)R Condorelli, F Mosele, B Verret, et al.
Pageof 4